Quick Answer
Aptevo Therapeutics Inc. reported Cash and Equivalents of $21.62 million for fiscal year 2025.
Aptevo Therapeutics Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $21.62M | +148.1% |
| 2024 | $8.71M | -48.5% |
| 2023 | $16.90M | -25.3% |
| 2022 | $22.64M | -49.7% |
| 2021 | $45.04M | +12.7% |
| 2020 | $39.98M | +221.2% |
| 2019 | $12.45M | -59.4% |
| 2018 | $30.64M | +331.8% |
| 2017 | $7.09M | -26.7% |
| 2016 | $9.68M | +108.7% |
| 2015 | $4.64M | +29.1% |
| 2014 | $3.59M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $21.06M | +171.6% | +123.8% |
| June 30, 2025 | $9.41M | +16.7% | +339.9% |
| March 31, 2025 | $2.14M | -79.1% | -75.5% |
| December 31, 2024 | $8.71M | -48.5% | +12.4% |
| September 30, 2024 | $7.75M | -59.4% | -3.9% |
| June 30, 2024 | $8.07M | -61.6% | -21.3% |
| March 31, 2024 | $10.25M | -59.5% | -39.4% |
| December 31, 2023 | $16.90M | -25.3% | -11.5% |
- Aptevo Therapeutics Inc. showed an increase of +148.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2014–2025 period, Aptevo Therapeutics Inc.’s cash and equivalents has grown by 501.7% (from $3.59 million to $21.62 million).
- The most recent figure is from Aptevo Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: